Q&A
Exclusive interviews with industry leaders
-
Permission granted by GSK
This GSK clinical data leader embraces the ‘Rubik’s cube’ problem: solving for all sides at once
The clinical data space is rapidly changing the face of the industry, GSK's Mayank Anand said — and the way organizations adopt technology is a critical part of the equation.
Michael Gibney • March 23, 2023 -
Permission granted by Babson Diagnostics
Babson aims to shed Theranos curse with new blood testing tech
Babson Diagnostics is trying to create a less invasive blood testing technology — can it gain trust in the post-Theranos era?
Kelly Bilodeau • March 13, 2023 -
Permission granted by Murray Aitken/IQVIA Institute
IQVIA’s OG of data analytics on the latest clinical trial trends
IQVIA Institute’s Murray Aitken is the man behind the numbers, and here, shares the newest findings on clinical trial burnout, diversity and more.
Taren Grom • March 10, 2023 -
Permission granted by Faeth
While many leverage precision medicine, Faeth is banking on precision nutrition to tackle cancer
The San Francisco-based biotech is pairing metabolically-engineered diets with existing therapies to starve and kill tumors.
Karissa Waddick • March 9, 2023 -
iStock via Getty Images
The ‘recovering academic’ leading Allogene to the next stage of cell therapy
Zachary Roberts joined Allogene at the beginning of this year to lead the company's R&D and bring allogeneic cell therapy to the forefront.
Michael Gibney • March 2, 2023 -
Christoph Burgstedt via Getty Images
Launched with a ‘pioneer’ in RNA, aTyr Pharma is charting a new course in immunology
With a focus on rare and hard-to-treat diseases, aTyr is banking on its head start in tRNA and vast IP portfolio to build a billion-dollar company.
Taren Grom • March 2, 2023 -
Permission granted by Dr. Faby Malik, Cytokinetics
Cytokinetics looks to muscle into the cardiovascular market
With a scientific platform based on muscle biology, the late-stage biotech is addressing cardiovascular and neuromuscular diseases.
Taren Grom • Feb. 24, 2023 -
Stock via Getty Images
Why patient care is a public affair
The VP of public affairs at Kyowa Kirin discusses her role in advocating for advocacy.
Taren Grom • Feb. 23, 2023 -
Stock via Getty Images
Pheast’s new CEO on how its ‘don’t eat me’ platform could deliver next-gen precision immunotherapies
Jacopo Leonardi’s latest venture is in the burgeoning field of macrophage inhibitors that could target a wide range of cancers.
Taren Grom • Feb. 17, 2023 -
iStock via Getty Images
Nectin’s Keytruda combo could fill gaps in immuno-oncology’s treatment paradigm
The Israeli biotech just entered into a collaboration with Merck to develop its own checkpoint inhibitor alongside the bestselling cancer treatment.
Michael Gibney • Feb. 16, 2023 -
Permission granted by Dr. William Chou, Passage Bio
Managing for resilience: Passage’s ups and downs in gene therapy
After a rocky year, Passage Bio’s CEO is focused on helping the rare disease specialist bounce back.
Meagan Parrish • Feb. 15, 2023 -
Permission granted by Klick Group
Brian Fox is bringing ‘fresh eyes’ to ad agency Klick
Why the recently appointed president of commercial solutions sees near limitless potential to expand Klick’s footprint across the life sciences — and how generative AI is playing a role.
Karissa Waddick • Feb. 13, 2023 -
Permission granted by Kinnari Patel Rocket Pharmaceuticals
Rocket Pharmaceuticals is ready for liftoff in the rare disease space
With two rare disease products on the launch pad for FDA submission in 2023 and a growing pipeline, Rocket is fueled for its next era of growth.
Taren Grom • Feb. 10, 2023 -
Permission granted by Entact Bio
Entact Bio’s CEO is leading the company out of stealth and into a new age of protein enhancement
Victoria Richon’s latest venture is in the burgeoning field of protein-enhancing drugs that could target a range of diseases.
Kelly Bilodeau • Feb. 6, 2023 -
Permission granted by Jill Milne, Astria Therapeutics
Astria Therapeutics’ edge in an ultra-rare disease
With positive early phase data, CEO Jill Milne is aiming to bring an improved preventative option to patients with hereditary angioedema.
Taren Grom • Feb. 1, 2023 -
Permission granted by CinCor
This biotech CEO secured two billion-dollar Big Pharma deals during the pandemic
With the industry focused on cancer and COVID-19, Marc de Garidel made deals centered on cardio.
Michael Gibney • Jan. 31, 2023 -
Permission granted by Gilead Sciences
Gilead’s commercial chief on why 2023 will be a ‘coming out’ year
With a rapidly expanding oncology pipeline and a new approval in HIV, Johanna Mercier discusses Gilead’s quest to transform.
Meagan Parrish • Jan. 26, 2023 -
Permission granted by Astellas
Already on a roll in oncology, Astellas hunts for big wins in other areas
With two potential first-in-class drug launches on the horizon, and a budding gene therapy business, Astellas believes this year could be a major inflection point.
Karissa Waddick • Jan. 23, 2023 -
Permission granted by Bekki Brown
UBC crowns Bekki Brown as its new CEO with a clear mandate to grow
The first-time CEO is tapping into decades of operational expertise to help bring real-world data into the mainstream.
Taren Grom • Jan. 20, 2023 -
Permission granted by CytomX
A Moderna tie-up ushers in new era for CytomX
The antibody-focused company followed up a tough year with big partnerships to keep the ball rolling.
Michael Gibney • Jan. 18, 2023 -
Permission granted by Hans Schambye
Galecto has identified a master switch to reduce fibroid formation
With expertise surrounding a natural family of proteins and enzymes that can lead to fibrosis, Galecto is exploring the potential to develop cancer treatments.
Taren Grom • Jan. 11, 2023 -
Stock via Getty Images
Gracell Biotechnologies’ quest to unlock the CAR-T bottleneck
The biotech hopes to upend the CAR-T category by cutting manufacturing from weeks to hours and developing a first-line cell therapy.
Taren Grom • Jan. 9, 2023 -
iStock via Getty Images
To drive trial diversity, one company is bringing them to the patient
For Lightship, increasing patient access to clinical trials is about meeting them where they are — literally.
Karissa Waddick • Dec. 21, 2022 -
Stock via Getty Images
Dr. Sy Pretorius, Eversana’s new COO, is flipping the script on his career
With a long history in the clinical space, Pretorius is now applying those deep insights to the commercial side of the business.
Taren Grom • Dec. 9, 2022 -
Permission granted by Takeda
Takeda’s global quest for health equity
Takeda’s Center for Health Equity and Patient Affairs is built to address health inequality around the world and aims to raise the bar for the pharma industry.
Taren Grom • Dec. 8, 2022
